title: Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.
abstract: Mobilization of Philadelphia chromosome (Ph) negative blood progenitors was attempted in 23 newly diagnosed chronic myeloid leukaemia (CML) patients using a regimen of cyclophosphamide (CY) 5 g/m2 and rHUG-CSF 150 microg/m2 daily. This regimen was well tolerated with no major adverse events reported. More than 2 x 10(6)/kg CD34+ cells were collected in 21 patients (91%). Predominantly Ph-negative mobilization (0-25% Ph-positive) was seen in 30% of cases overall and was confined to patients with a Sokal prognostic score < 1 (7/11 with Sokal score <1; 0/12 with Sokal score > or = 1). Within the low Sokal index group, a low WBC count pre-mobilization and a low WBC nadir both correlated strongly with Ph-negative mobilization (P = 0.006 and 0.02 respectively). Five of 19 patients receiving at least 6 months of Roferon A therapy post mobilization achieved a major cytogenetic response; all five patients were Ph-negative mobilizers. Therefore CML patients can be divided into a good-prognosis group in whom predominantly Ph-negative progenitors can be mobilized using a regimen of moderate intensity if haematological control is achieved pre-mobilization, and a poor-prognosis group for whom predominantly Ph-positive cells are mobilized with this regimen regardless of haematological control.
authors.affiliation: Royal Adelaide Hospital, Australia.
authors.forename: T P
authors.initials: TP
authors.lastname: Hughes
authors.forename: A
authors.initials: A
authors.lastname: Grigg
authors.forename: J
authors.initials: J
authors.lastname: Szer
authors.forename: J
authors.initials: J
authors.lastname: Ho
authors.forename: D
authors.initials: D
authors.lastname: Ma
authors.forename: B M
authors.initials: BM
authors.lastname: Dale
authors.forename: R M
authors.initials: RM
authors.lastname: Green
authors.forename: J E
authors.initials: JE
authors.lastname: Norman
authors.forename: R E
authors.initials: RE
authors.lastname: Sage
authors.forename: R
authors.initials: R
authors.lastname: Herrmann
authors.forename: P
authors.initials: P
authors.lastname: Cannell
authors.forename: A P
authors.initials: AP
authors.lastname: Schwarer
authors.forename: K
authors.initials: K
authors.lastname: Taylor
authors.forename: K
authors.initials: K
authors.lastname: Atkinson
authors.forename: C
authors.initials: C
authors.lastname: Arthur
mesh_terms: D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007937:Leukapheresis; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide